{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T05:47:46Z","timestamp":1768715266565,"version":"3.49.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T00:00:00Z","timestamp":1560556800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T00:00:00Z","timestamp":1560556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12883-019-1354-y","type":"journal-article","created":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T08:02:52Z","timestamp":1560585772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists"],"prefix":"10.1186","volume":"19","author":[{"name":"on behalf of the members of an expert meeting","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Kolb-M\u00e4urer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cord","family":"Sunderk\u00f6tter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borries","family":"Kukowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven G.","family":"Meuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,15]]},"reference":[{"key":"1354_CR1","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1098\/rspb.1957.0048","volume":"147","author":"A Isaacs","year":"1957","unstructured":"Isaacs A, Lindenmann J. Virus interference. I. the interferon. Proc R Soc London Ser B, Biol Sci. 1957;147:258\u201367 \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/13465720\n                    \n                  . Accessed 2 Apr 2017.","journal-title":"Proc R Soc London Ser B, Biol Sci"},{"key":"1354_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1468-1331.2010.03110.x","volume":"18","author":"V Devonshire","year":"2011","unstructured":"Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, Fontoura P, et al. The global adherence project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2011;18:69\u201377. \n                    https:\/\/doi.org\/10.1111\/j.1468-1331.2010.03110.x\n                    \n                  .","journal-title":"Eur J Neurol"},{"key":"1354_CR3","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/S1474-4422(14)70100-0","volume":"13","author":"H-P Hartung","year":"2014","unstructured":"Hartung H-P. Interferon \u03b2-1a for multiple sclerosis: old drug, new clothes. Lancet Neurol. 2014;13:638\u20139. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(14)70100-0\n                    \n                  .","journal-title":"Lancet Neurol"},{"key":"1354_CR4","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1089\/jir.2010.0092","volume":"30","author":"DP Baker","year":"2010","unstructured":"Baker DP, Pepinsky RB, Brickelmaier M, Gronke RS, Hu X, Olivier K, et al. PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis. J Interf Cytokine Res. 2010;30:777\u201385. \n                    https:\/\/doi.org\/10.1089\/jir.2010.0092\n                    \n                  .","journal-title":"J Interf Cytokine Res"},{"issue":"Suppl 1","key":"1354_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1055\/s-2003-41631","volume":"23","author":"S Zeuzem","year":"2003","unstructured":"Zeuzem S, Welsch C, Herrmann E, Ph D. Pharmacokinetics of peginterferons. Semin Liver Dis. 2003;23(Suppl 1):23\u20138. \n                    https:\/\/doi.org\/10.1055\/s-2003-41631\n                    \n                  .","journal-title":"Semin Liver Dis"},{"key":"1354_CR6","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1056\/NEJM200012073432301","volume":"343","author":"S Zeuzem","year":"2000","unstructured":"Zeuzem S, Feinman VR, Heathcote J, Ming-Yang L, Gane D, O\u2019grady J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666\u201372.","journal-title":"N Engl J Med"},{"key":"1354_CR7","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1053\/jhep.2001.26371","volume":"34","author":"KL Lindsay","year":"2001","unstructured":"Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34:395\u2013403.","journal-title":"Hepatology."},{"key":"1354_CR8","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1177\/0091270011407068","volume":"52","author":"X Hu","year":"2012","unstructured":"Hu X, Miller L, Richman S, Hitchman S, Glick G, Liu S, et al. A novel PEGylated interferon Beta-1a for multiple sclerosis: safety, pharmacology, and biology. J Clin Pharmacol. 2012;52:798\u2013808. \n                    https:\/\/doi.org\/10.1177\/0091270011407068\n                    \n                  .","journal-title":"J Clin Pharmacol"},{"key":"1354_CR9","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/bcp.12968","volume":"82","author":"X Hu","year":"2016","unstructured":"Hu X, Shang S, Nestorov I, Hasan J, Seddighzadeh A, Dawson K, et al. COMPARE: pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects. Br J Clin Pharmacol. 2016;82:380\u20138. \n                    https:\/\/doi.org\/10.1111\/bcp.12968\n                    \n                  .","journal-title":"Br J Clin Pharmacol"},{"key":"1354_CR10","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1177\/1352458514557986","volume":"21","author":"BC Kieseier","year":"2015","unstructured":"Kieseier BC, Arnold DL, Balcer LJ, Boyko AA, Pelletier J, Liu S, et al. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler. 2015;21:1025\u201335. \n                    https:\/\/doi.org\/10.1177\/1352458514557986\n                    \n                  .","journal-title":"Mult Scler"},{"key":"1354_CR11","volume-title":"ADVANCE phase 3 extension study (ATTAIN): Peginterferon beta-1a 125 mcg every 2 weeks demonstrated sustained efficacy in RMS patients treated up to 5 years. AAN","author":"D Fiore","year":"2016","unstructured":"Fiore D et al. ADVANCE phase 3 extension study (ATTAIN): Peginterferon beta-1a 125 mcg every 2 weeks demonstrated sustained efficacy in RMS patients treated up to 5 years. AAN 2016; P4.010."},{"key":"1354_CR12","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","volume":"13","author":"PA Calabresi","year":"2014","unstructured":"Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014;13:657\u201365. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(14)70068-7\n                    \n                  .","journal-title":"Lancet Neurol"},{"key":"1354_CR13","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1056\/NEJMoa1501481","volume":"373","author":"L Kappos","year":"2015","unstructured":"Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A, et al. Daclizumab HYP versus interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med. 2015;373:1418\u201328. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1501481\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"1354_CR14","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1177\/1352458512438239","volume":"18","author":"DM Balak","year":"2012","unstructured":"Balak DM, Hengstman GJ, Cakmak A, Thio HB. Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review. Mult Scler J. 2012;18:1705\u201317. \n                    https:\/\/doi.org\/10.1177\/1352458512438239\n                    \n                  .","journal-title":"Mult Scler J"},{"key":"1354_CR15","doi-asserted-by":"publisher","first-page":"14951","DOI":"10.3390\/ijms160714951","volume":"16","author":"A Kolb-M\u00e4urer","year":"2015","unstructured":"Kolb-M\u00e4urer A, Goebeler M, M\u00e4urer M. Cutaneous adverse events associated with interferon-\u03b2 treatment of multiple sclerosis. Int J Mol Sci. 2015;16:14951\u201360. \n                    https:\/\/doi.org\/10.3390\/ijms160714951\n                    \n                  .","journal-title":"Int J Mol Sci"},{"key":"1354_CR16","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jneuroim.2005.07.011","volume":"168","author":"M Buttmann","year":"2005","unstructured":"Buttmann M, Goebeler M, Toksoy A, Schmid S, Graf W, Berberich-Siebelt F, et al. Subcutaneous interferon-\u03b2 injections in patients with multiple sclerosis initiate inflammatory skin reactions by local chemokine induction. J Neuroimmunol. 2005;168:175\u201382. \n                    https:\/\/doi.org\/10.1016\/j.jneuroim.2005.07.011\n                    \n                  .","journal-title":"J Neuroimmunol"},{"key":"1354_CR17","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1212\/WNL.53.8.1622","volume":"53","author":"EU Walther","year":"1999","unstructured":"Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology. 1999;53:1622. \n                    https:\/\/doi.org\/10.1212\/WNL.53.8.1622\n                    \n                  .","journal-title":"Neurology."},{"key":"1354_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2217\/nmt-2016-0032","volume":"7","author":"B Hendin","year":"2017","unstructured":"Hendin B, Huang D, Wray S, Naismith RT, Rosenblatt S, Zambrano J, et al. Subcutaneous peginterferon \u03b2-1a injection-site reaction experience and mitigation: Delphi analysis of the ALLOW study. Neurodegener Dis Manag. 2017;7:39\u201347. \n                    https:\/\/doi.org\/10.2217\/nmt-2016-0032\n                    \n                  .","journal-title":"Neurodegener Dis Manag"},{"key":"1354_CR19","unstructured":"Plegridy\u00ae, Summary of Product Characteristics. \n                    http:\/\/ec.europa.eu\/health\/documents\/community-register\/2014\/20140718129034\/anx_129034_en.pdf\n                    \n                  . Accessed 3 Apr 2017."},{"key":"1354_CR20","volume-title":"ADVANCE phase 3 extension study (ATTAIN): Peginterferon beta-1a safety and tolerability remain favorable in RMS patients with up to 5 years of treatment. AAN","author":"Y Cui","year":"2016","unstructured":"Cui Y et al. ADVANCE phase 3 extension study (ATTAIN): Peginterferon beta-1a safety and tolerability remain favorable in RMS patients with up to 5 years of treatment. AAN 2016; P5.403."},{"key":"1354_CR21","unstructured":"Avonex\u00ae, Summary of Product Characteristics. \n                    https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/avonex-epar-product-information_en.pdf\n                    \n                   Accessed 25 Apr 2019."},{"key":"1354_CR22","unstructured":"Rebif\u00ae, Summary of Product Characteristics. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000136\/WC500048681.pdf\n                    \n                  . Accessed 3 Apr 2017."},{"key":"1354_CR23","unstructured":"Betaferon\u00ae, Summary of Product Characteristics. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000081\/WC500053225.pdf\n                    \n                  . Accessed 3 Apr 2017."},{"key":"1354_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.7224\/1537-2073.2015-042","volume":"18","author":"J Halper","year":"2016","unstructured":"Halper J, Centonze D, Newsome SD, Huang D, Robertson C, You X, et al. Management strategies for flu-like symptoms and injection-site reactions associated with Peginterferon Beta-1a. Int J MS Care. 2016;18:211\u20138. \n                    https:\/\/doi.org\/10.7224\/1537-2073.2015-042\n                    \n                  .","journal-title":"Int J MS Care"},{"key":"1354_CR25","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1191\/1352458504ms1002oa","volume":"10","author":"EM Frohman","year":"2004","unstructured":"Frohman EM, Brannon K, Alexander S, Sims D, Phillips JT, O\u2019Leary S, et al. Disease modifying agent related skin reactions in multiple sclerosis: prevention, assessment, and management. Mult Scler. 2004;10:302\u20137. \n                    https:\/\/doi.org\/10.1191\/1352458504ms1002oa\n                    \n                  .","journal-title":"Mult Scler"},{"key":"1354_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-015-0426-x","volume":"15","author":"Z Katsarava","year":"2015","unstructured":"Katsarava Z, Ehlken B, Limmroth V, Taipale K, Patel SN, Niemczyk G, et al. Adherence and cost in multiple sclerosis patients treated with IM IFN beta-1a: impact of the CARE patient management program. BMC Neurol. 2015;15:170. \n                    https:\/\/doi.org\/10.1186\/s12883-015-0426-x\n                    \n                  .","journal-title":"BMC Neurol"},{"key":"1354_CR27","unstructured":"A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in MS - Full Text View - \n                    ClinicalTrials.gov\n                    \n                  . \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02490943?term=peginterferon+beta-1a&rank=11\n                    \n                  . Accessed 2 Apr 2017."},{"key":"1354_CR28","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/exd.12555","volume":"23","author":"T Hawro","year":"2014","unstructured":"Hawro T, Fluhr JW, Mengeaud V, Redoul\u00e8s D, Church MK, Maurer M, et al. Polidocanol inhibits cowhage - but not histamine-induced itch in humans. Exp Dermatol. 2014;23:922\u20133. \n                    https:\/\/doi.org\/10.1111\/exd.12555\n                    \n                  .","journal-title":"Exp Dermatol"},{"key":"1354_CR29","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1600-0536.2010.01830.x","volume":"64","author":"A Leroy","year":"2011","unstructured":"Leroy A, Baeck M, Tennstedt D. Contact dermatitis and secondary systemic allergy to dimethindene maleate. Contact Dermatitis. 2011;64:170\u20131. \n                    https:\/\/doi.org\/10.1111\/j.1600-0536.2010.01830.x\n                    \n                  .","journal-title":"Contact Dermatitis"},{"key":"1354_CR30","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/j.1600-0536.2009.01638.x","volume":"61","author":"A Jocher","year":"2009","unstructured":"Jocher A, Nist G, Weiss JM, Wetzel D, Merfort I, Jakob T, et al. Allergenic potential of Arnica-containing formulations in Arnica-allergic patients. Contact Dermatitis. 2009;61:304\u20136. \n                    https:\/\/doi.org\/10.1111\/j.1600-0536.2009.01638.x\n                    \n                  .","journal-title":"Contact Dermatitis"},{"key":"1354_CR31","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1177\/1352458514562989","volume":"21","author":"R Lanzillo","year":"2015","unstructured":"Lanzillo R, Moccia M, Carotenuto A, Vacchiano V, Satelliti B, Panetta V, Brescia Morra V. Vitamin K cream reduces reactions at the injection site in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon beta - VIKING study. Mult Scler. 2015;21:1215\u20136.","journal-title":"Mult Scler"},{"key":"1354_CR32","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1191\/1352458503ms933sr","volume":"9","author":"F Casoni","year":"2003","unstructured":"Casoni F, Merelli E, Bedin R, Martella A, Cesinaro A, Bertolotto A. Necrotizing skin lesions and NABs development in a multiple sclerosis patient treated with IFNbeta 1b. Mult Scler. 2003;9:420\u20133. \n                    https:\/\/doi.org\/10.1191\/1352458503ms933sr\n                    \n                  .","journal-title":"Mult Scler"},{"key":"1354_CR33","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/ana.410390304","volume":"39","author":"LD Jacobs","year":"1996","unstructured":"Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The multiple sclerosis collaborative research group (MSCRG). Ann Neurol. 1996;39:285\u201394. \n                    https:\/\/doi.org\/10.1002\/ana.410390304\n                    \n                  .","journal-title":"Ann Neurol"},{"key":"1354_CR34","doi-asserted-by":"crossref","unstructured":"Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group. Neurology. 1995;45:1277\u201385 \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7617182\n                    \n                  . Accessed 4 Sep 2016.","DOI":"10.1212\/WNL.45.7.1277"},{"key":"1354_CR35","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1212\/WNL.56.12.1628","volume":"56","author":"PRISMS Study Group and the University of British Columbia MS\/MRI Analysis Group","year":"2001","unstructured":"PRISMS Study Group and the University of British Columbia MS\/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 2001;56:1628\u201336 \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11425926\n                    \n                  . Accessed 14 Dec 2016.","journal-title":"Neurology."},{"key":"1354_CR36","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1212\/WNL.46.1.12","volume":"46","author":"FD Lublin","year":"1996","unstructured":"Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BG, Burks JS. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology. 1996;46:12\u20138 \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8559358\n                    \n                  . Accessed 2 Apr 2017.","journal-title":"Neurology."},{"key":"1354_CR37","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.clineuro.2010.12.013","volume":"113","author":"Y Nadjar","year":"2011","unstructured":"Nadjar Y, Coutelas E, Prouteau P, Panzer F, Paquet D, Saint-Val C, et al. Injection of interferon-beta in the morning decreases flu-like syndrome in many patients with multiple sclerosis. Clin Neurol Neurosurg. 2011;113:316\u201322. \n                    https:\/\/doi.org\/10.1016\/j.clineuro.2010.12.013\n                    \n                  .","journal-title":"Clin Neurol Neurosurg"},{"key":"1354_CR38","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1191\/1352458505ms1162oa","volume":"11","author":"Goldman Consensus Group","year":"2005","unstructured":"Goldman Consensus Group. The Goldman consensus statement on depression in multiple sclerosis. Mult Scler. 2005;11:328\u201337.","journal-title":"Mult Scler"},{"key":"1354_CR39","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1212\/WNL.0000000000000013","volume":"82","author":"SL Minden","year":"2014","unstructured":"Minden SL, Feinstein A, Kalb RC, Miller D, Mohr DC, Patten SB, et al. Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the guideline development Subcommittee of the American Academy of neurology. Neurology. 2014;82:174\u201381. \n                    https:\/\/doi.org\/10.1212\/WNL.0000000000000013\n                    \n                  .","journal-title":"Neurology."},{"key":"1354_CR40","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1177\/135245850000600509","volume":"6","author":"A Feinstein","year":"2000","unstructured":"Feinstein A. Multiple sclerosis, disease modifying treatments and depression: a critical methodological review. Mult Scler J. 2000;6:343\u20138. \n                    https:\/\/doi.org\/10.1177\/135245850000600509\n                    \n                  .","journal-title":"Mult Scler J"},{"key":"1354_CR41","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1007\/s00415-016-8146-8","volume":"263","author":"S Schippling","year":"2016","unstructured":"Schippling S, O\u2019Connor P, Knappertz V, Pohl C, Bogumil T, Suarez G, et al. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol. 2016;263:1418\u201326.","journal-title":"J Neurol"},{"key":"1354_CR42","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.eurpsy.2005.09.013","volume":"21","author":"JL Goeb","year":"2006","unstructured":"Goeb JL, Even C, Nicolas G, Gohier B, Dubas F, Garr\u00e9 JB. Psychiatric side effects of interferon-beta in multiple sclerosis. Eur Psychiatry. 2006;21:186\u201393.","journal-title":"Eur Psychiatry"},{"issue":"1","key":"1354_CR43","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/00002826-200301000-00002","volume":"26","author":"J. L. Go\u00ebb","year":"2003","unstructured":"Go\u00ebb JL, Cailleau A, Lain\u00e9 P, Etcharry-Bouyx F, Maugin D, Duverger P, et al. Acute delirium, delusion, and depression during IFN-beta-1a therapy for multiple sclerosis: a case report. Clin Neuropharmacol. 26:5\u20137 \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12567157\n                    \n                  . Accessed 2 Apr 2017.","journal-title":"Clinical Neuropharmacology"},{"key":"1354_CR44","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1177\/070674370204700720","volume":"47","author":"R Pandya","year":"2002","unstructured":"Pandya R, Patten S. Depression in multiple sclerosis associated with interferon beta-1a (Rebif). Can J Psychiatr. 2002;47:686. \n                    https:\/\/doi.org\/10.1177\/070674370204700720\n                    \n                  .","journal-title":"Can J Psychiatr"},{"key":"1354_CR45","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1177\/1352458511401943","volume":"17","author":"F Patti","year":"2011","unstructured":"Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Picconi O, et al. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive impairment in MUltiple sclerosis) study. Mult Scler. 2011;17:991\u20131001. \n                    https:\/\/doi.org\/10.1177\/1352458511401943\n                    \n                  .","journal-title":"Mult Scler"},{"key":"1354_CR46","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1212\/WNL.0000000000004037","volume":"88","author":"H de Jong","year":"2017","unstructured":"de Jong H, Kingwell E, Shirani A, et al. Evaluating the safety of b-interferons in MS. Neurology. 2017;88:2310\u201320.","journal-title":"Neurology"},{"key":"1354_CR47","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2165\/00002018-199410020-00003","volume":"10","author":"T Vial","year":"1994","unstructured":"Vial T, Descotes J. Clinical toxicity of the interferons. Drug Saf. 1994;10:115\u201350 \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7516663\n                    \n                  . Accessed 19 Feb 2017.","journal-title":"Drug Saf"},{"key":"1354_CR48","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2165\/00002018-200427100-00005","volume":"27","author":"P Rieckmann","year":"2004","unstructured":"Rieckmann P, O\u2019Connor P, Francis GS, Wetherill G, Alteri E. Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis. Drug Saf. 2004;27:745\u201356 \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15350158\n                    \n                  . Accessed 19 Feb 2017.","journal-title":"Drug Saf"},{"key":"1354_CR49","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00415-004-0619-5","volume":"251","author":"H Tremlett","year":"2004","unstructured":"Tremlett H, Oger J. Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis. J Neurol. 2004;251:1297\u2013303. \n                    https:\/\/doi.org\/10.1007\/s00415-004-0619-5\n                    \n                  .","journal-title":"J Neurol"},{"key":"1354_CR50","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10238-004-0026-3","volume":"3","author":"F Monzani","year":"2004","unstructured":"Monzani F, Caraccio N, Dardano A, Ferrannini E. Thyroid autoimmunity and dysfunction associated with type I interferon therapy. Clin Exp Med. 2004;3:199\u2013210. \n                    https:\/\/doi.org\/10.1007\/s10238-004-0026-3\n                    \n                  .","journal-title":"Clin Exp Med"},{"key":"1354_CR51","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00115-016-0077-1","volume":"87","author":"L Klotz","year":"2016","unstructured":"Klotz L, Berthele A, Br\u00fcck W, Chan A, Flachenecker P, Gold R, et al. Monitoring von Blutparametern unter verlaufsmodifizierender MS-Therapie. Nervenarzt. 2016;87:645\u201359. \n                    https:\/\/doi.org\/10.1007\/s00115-016-0077-1\n                    \n                  .","journal-title":"Nervenarzt."},{"key":"1354_CR52","unstructured":"Qualit\u00e4tshandbuch Multiple Sklerose. \n                    http:\/\/www.kompetenznetz-multiplesklerose.de\/wp-content\/uploads\/2016\/12\/KKNMS_Handbuch_Gesamtausgabe_verknuepft_20160914_webfrei.pdf\n                    \n                  . Accessed 17 Dec 2016."}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-019-1354-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-019-1354-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-019-1354-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T23:03:57Z","timestamp":1592089437000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-019-1354-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,15]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1354"],"URL":"https:\/\/doi.org\/10.1186\/s12883-019-1354-y","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,15]]},"assertion":[{"value":"21 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AKM has received honoraria for lecturing and travel expenses for attending meetings from Biogen.BK has received honoraria for lecturing and travel expenses for attending meetings from Biogen, Genzyme, Novartis, Roche, Sanofi-Aventis and Teva.CS has received honoraria for lecturing and travel expenses for attending meetings from Biogen.SGM has received honoraria for lecturing, travel expenses for attending meetings and financial research support from Almirall, Bayer Health Care, Biogen, Diamed, Genzyme, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis and Teva.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"130"}}